Tildrakizumab

Tildrakizumab was efficacious and safe in treating plaque psoriasis over 4 years, according to a study presented at the American Academy of Dermatology virtual meeting.

MIAMI BEACH, Fla. — Anti-interleukin-23 agents tildrakizumab, guselkumab, risankizumab and mirikizumab are effective in treating patients with psoriasis, with one of the longest remission durations of any drug currently in use, according to a presenter at South Beach Symposium.

In the most popular Healio Dermatology story last week, Suzanne Bruce, MD, presented findings at the American Society for Dermatologic Surgery annual meeting from her research weighing the positives and negatives of private equity to help her decide how to transition her dermatology practice to allow more time with her family.

Metabolic syndrome status numerically affected the median Psoriasis Area and Severity Index score changes in patients receiving Ilumya 100 mg or 200 mg or Enbrel but was not clinically lower, according to research presented at the Academy of Managed Care Pharmacy Nexus.

Ilumya is among the most cost-effective first-line therapies for treating psoriasis, according to research presented by Justin Carrico, MD, of RTI Health Solutions, and colleagues at Academy of Managed Care Pharmacy Nexus.

The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.